These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 31345226)

  • 21. Trends towards more active introduction of drug therapy, emphasizing methotrexate and biologic agents, for juvenile idiopathic arthritis.
    Pohjankoski H; Kautiainen H; Lauri JV; Puolakka K; Rantalaiho V
    Clin Rheumatol; 2020 Jan; 39(1):263-268. PubMed ID: 31346886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration.
    Fráňová J; Fingerhutová Š; Kobrová K; Srp R; Němcová D; Hoza J; Uher M; Saifridová M; Linková L; Doležalová P
    Pediatr Rheumatol Online J; 2016 Jun; 14(1):36. PubMed ID: 27301536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of methotrexate in children with rheumatic diseases.
    Gutiérrez-Suárez R; Burgos-Vargas R
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S122-7. PubMed ID: 21044445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors determining resistance to conventional disease-modifying anti-rheumatic drug treatment in oligoarticular juvenile idiopathic arthritis.
    Sener S; Aliyev E; Batu ED; Balik Z; Bayindir Y; Cam V; Basaran O; Bilginer Y; Ozen S
    Clin Rheumatol; 2024 Jun; 43(6):2021-2026. PubMed ID: 38683443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. When should the use of biological agents be considered in persistent oligoarticular juvenile idiopathic arthritis patients?
    Polat MC; Çelikel E; Tekin ZE; Kurt T; Kaplan MM; Güngörer V; Tekgöz N; Sezer M; Karagöl C; Coşkun S; Öner N; Sezer S; Acar BÇ
    Eur J Pediatr; 2024 Jun; 183(6):2725-2731. PubMed ID: 38554171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans.
    Kimura Y; Grevich S; Beukelman T; Morgan E; Nigrovic PA; Mieszkalski K; Graham TB; Ibarra M; Ilowite N; Klein-Gitelman M; Onel K; Prahalad S; Punaro M; Ringold S; Toib D; Van Mater H; Weiss JE; Weiss PF; Schanberg LE;
    Pediatr Rheumatol Online J; 2017 Apr; 15(1):23. PubMed ID: 28399931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA.
    Klotsche J; Minden K; Niewerth M; Horneff G
    Ann Rheum Dis; 2018 Jul; 77(7):996-1002. PubMed ID: 29453217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abatacept as Monotherapy and in Combination With Methotrexate in Patients With Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials.
    Ruperto N; Lovell DJ; Berman A; Anton J; Viola DO; Lauwerys B; Rama ME; Bohnsack J; Breedt J; Fischbach M; Lutz T; Minden K; Ally M; Rubio-Pérez N; Gervais E; Van Zyl R; Wong R; Askelson M; Martini A; Brunner HI;
    J Rheumatol; 2023 Nov; 50(11):1471-1480. PubMed ID: 37453737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In the Pursuit of Methotrexate Treatment Response Biomarker in Juvenile Idiopathic Arthritis-Are We Getting Closer to Personalised Medicine?
    Roszkiewicz J; Smolewska E
    Curr Rheumatol Rep; 2017 Apr; 19(4):19. PubMed ID: 28361333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting.
    Ferrara G; Mastrangelo G; Barone P; La Torre F; Martino S; Pappagallo G; Ravelli A; Taddio A; Zulian F; Cimaz R;
    Pediatr Rheumatol Online J; 2018 Jul; 16(1):46. PubMed ID: 29996864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.
    Lovell DJ; Brunner HI; Reiff AO; Jung L; Jarosova K; Němcová D; Mouy R; Sandborg C; Bohnsack JF; Elewaut D; Gabriel C; Higgins G; Kone-Paut I; Jones OY; Vargová V; Chalom E; Wouters C; Lagunes I; Song Y; Martini A; Ruperto N
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increasing the etanercept dose in a treat-to-target approach in juvenile idiopathic arthritis: does it help to reach the target? A post-hoc analysis of the BeSt for Kids randomised clinical trial.
    van Dijk BT; Bergstra SA; van den Berg JM; Schonenberg-Meinema D; van Suijlekom-Smit LWA; van Rossum MAJ; Koopman-Keemink Y; Ten Cate R; Allaart CF; Brinkman DMC; Hissink Muller PCE
    Pediatr Rheumatol Online J; 2024 May; 22(1):53. PubMed ID: 38730442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A longterm prospective real-life experience with leflunomide in juvenile idiopathic arthritis.
    Alcântara AC; Leite CA; Leite AC; Sidrim JJ; Silva FS; Rocha FA
    J Rheumatol; 2014 Feb; 41(2):338-44. PubMed ID: 24334641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).
    Davies R; Carrasco R; Foster HE; Baildam EM; Chieng SEA; Davidson JE; Ioannou Y; Wedderburn LR; Thomson W; Hyrich KL
    Semin Arthritis Rheum; 2016 Oct; 46(2):190-195. PubMed ID: 27422803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis.
    Yue X; Huang B; Hincapie AL; Wigle PR; Qiu T; Li Y; Morgan EM; Guo JJ
    Paediatr Drugs; 2021 Mar; 23(2):171-182. PubMed ID: 33651370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance.
    Horton DB; Onel KB; Beukelman T; Ringold S
    J Rheumatol; 2017 Mar; 44(3):352-360. PubMed ID: 28148696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis.
    Ravelli A; Viola S; Migliavacca D; Ruperto N; Pistorio A; Martini A
    J Pediatr; 1999 Sep; 135(3):316-20. PubMed ID: 10484796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry.
    Beukelman T; Lougee A; Matsouaka RA; Collier D; Rumsey DG; Schenfeld J; Stryker S; Twilt M; Kimura Y;
    Pediatr Rheumatol Online J; 2021 Aug; 19(1):131. PubMed ID: 34419107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.
    Kimura Y; Schanberg LE; Tomlinson GA; Riordan ME; Dennos AC; Del Gaizo V; Murphy KL; Weiss PF; Natter MD; Feldman BM; Ringold S;
    Arthritis Rheumatol; 2021 Oct; 73(10):1898-1909. PubMed ID: 34105312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.